Nephros Inc (NEPH)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $33.15M
Last updated: Nov 17, 2026 at 11:00 AM ET
Nephros Inc (NEPH) Stock Forecast
Analysts expect Nephros (NEPH) to earn $0.17 per share in the fiscal year ending Dec 31, 2026, on revenue of $22.22M. Of 3 analysts, 2 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 67% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 33.3% |
| Buy | 1 | 33.3% |
| Hold | 1 | 33.3% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 23.5% and revenue estimates rise 15.5%.
- Fiscal year ending Dec 31, 2026
- $0.17
- EPS consensus, revenue $22.22M
- Fiscal year ending Dec 31, 2027
- $0.21
- EPS consensus, revenue $25.66M
- Next report
- Mar 10, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.17 | $0.17 to $0.17 | 1 | $22.22M | $22.07M to $22.35M | 3 |
| Dec 31, 2027 | $0.21 | $0.21 to $0.21 | 1 | $25.66M | $25.52M to $25.79M | 2 |
Quarterly Estimates
The EPS consensus rises from $0.01 for the quarter ending Dec 31, 2026 to $0.04 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.01 | $0.01 to $0.02 | 5 | $5.47M | $5.10M to $5.77M | 5 |
| Mar 31, 2027 | $0.04 | $0.04 to $0.04 | 1 | $5.97M | $5.88M to $6.06M | 2 |
Estimate Revisions
Across the 2 periods below, the last 30 days brought 1 upward and 0 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 240.0% from $0.05.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.17 | $0.17 | $0.04 | $0.05 | $0.05 | +277.8% |
| Fiscal year ending Dec 31, 2027 | $0.21 | $0.15 | $0.10 | $0.10 | $0.10 | +110.0% |
| Quarter ending Mar 31, 2027 | $0.04 | $0.03 | N/A | N/A | N/A | N/A |
Frequently Asked Questions About NEPH
What is the NEPH stock forecast?
Consensus analyst estimates put Nephros's EPS at $0.17 for the fiscal year ending Dec 31, 2026, on revenue of $22.22M. The consensus rating from 3 analysts is Buy.
How do analysts rate NEPH stock?
Of 3 analysts covering Nephros, 1 rates it Strong Buy, 1 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from NEPH next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.17, with estimates from $0.17 to $0.17 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.21, with estimates from $0.21 to $0.21 from 1 analyst.
What revenue do analysts expect from Nephros next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $22.22M, with estimates from $22.07M to $22.35M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $25.66M, with estimates from $25.52M to $25.79M.
How many analysts cover NEPH?
3 analysts rate Nephros stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
NEPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors